Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

Autor: Navneet Singh, Sarah Temin, Sherman Baker, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Andrew G. Robinson, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, David R. Spigel, Ishmael A. Jaiyesimi

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(28)

Living guidelines are routinely updated guidelines that are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. These guidelines are updated on a regular schedule, based on the work of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43fb38836918fde56f09c02e69029c3
https://pubmed.ncbi.nlm.nih.gov/35816666

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Autor: Nasser H. Hanna, Andrew G. Robinson, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, Navneet Singh, David R. Spigel, Joan Tashbar, Gregory Masters

Publikováno v: Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1475f7706c3538ad5279e534fb6e56d
https://pubmed.ncbi.nlm.nih.gov/34320333

Sickle cell disease; An overview of the disease and its systemic effects

Autor: Rami Y. Haddad, Sandra Mohama, Anne Ashley Compton, Danny Baghdan, Sahar Alrayyes, Nadia Kawar, Reihaneh Goreishi

Publikováno v: Disease-a-month : DM. 64(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::280a2933fcb216e777caec0e54647ecd
https://pubmed.ncbi.nlm.nih.gov/29395106

Chronic Lymphocytic Leukemia

Autor: Rami Y. Haddad, Mohammed Shanshal

Publikováno v: Disease-a-Month. 58:153-167

Mohammed Shanshal, MD, and Rami Y. Haddad, MD, FACP hronic lymphocytic leukemia [chronic lymphoid leukemia (CLL)] is a onoclonal disorder characterized by a progressive accumulation of unctionally incompetent lymphocytes. The most characteristic feat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1873373d5ef932600cb88b6df8ca7db
https://doi.org/10.1016/j.disamonth.2012.01.009

Current Concepts of Clinical Management of Multiple Myeloma

Autor: Ayman Saad, Rami Y. Haddad, Sai Ravi Pingali

Publikováno v: Disease-a-Month. 58:195-207

MM accounts for 1% of all malignancies and 10% of all hematological malignancies with 3-4 cases per 100,000. The incidence is highest among African Americans, then Caucasians, and is least common among Asians. It affects more men than women, with a r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f56ce09f7acbe18ef6f3afadaa2239
https://doi.org/10.1016/j.disamonth.2012.01.006